Trial Profile

A Phase 1, First-in-human, Randomized, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DWP213388 After SAD and MAD in Healthy Adult Subjects

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DWP 213388 (Primary)
Indications Chronic urticaria; Rheumatoid arthritis; Systemic lupus erythematosus
Focus Adverse reactions; First in man
Sponsors Daewoong Pharmaceutical

05 Nov 2024 Status changed from not yet recruiting to withdrawn prior to enrolment. (Withdrawal of Clinical Trial due to Licensing Out)
08 Nov 2022 Status changed from planning to not yet recruiting.
19 Aug 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com